Replies to post #298792 on Avid Bioservices Inc (CDMO)

[cjgaddy]

9-9-17/ESMO’17: Final SUNRISE Ph3 Data, Poster #1364P

Sept8-12 2017: “42nd ESMO European Cancer Congress”, Madrid
http://www.esmo.org/Conferences/ESMO-2017-Congress
ESMO = European Society for Medical Oncology
ECCO = European CanCer Organization
Pgm: http://www.esmo.org/Conferences/ESMO-2017-Congress/Programme
PEREGRINE EXHIBITING: BOOTH #257
9-9-17 1:15-2:15pm Poster #1364P:
“Final Clinical Results from SUNRISE: A Phase III Multicenter Trial of Bavituximab+Docetaxel in Patients with Prev. Treated Stage IIIb/IV nonsquamous NSCLC”
R. Palmero (Barcelona, Spain) P. Bidoli (Italy) I.M. Bondarenko (Ukraine) M. Boyer (Australia) P. Germonpre (Belgium) D. Ghizdavescu (Romania) A. Kotsakis (Greece) H. Lena (France) G. Losonczy (Hungary) K. Park (Korea) M. Reck (Germany) W. Su (Taiwan) N. Kallinteris (Tustin) M. Tang (Tustin) J. Lai (Tustin) J. Shan (Tustin) D.R. Spigel (Nashville TN)
ABSTRACT: https://cslide.ctimeetingtech.com/library/esmo/browse/search/5uD#2Bb5o
BACKGROUND:
Exposed phosphatidylserine (PS) in the tumor microenvironment is highly immunosuppressive. Bavituximab targets PS and repolarizes M2 macrophages to M1 resulting in production of pro-inflammatory cytokines such as IFN-y and IL-12, maturation of dendritic cells, and tumor specific cytotoxic T lymphocyte immunity. In a prior blinded Phase II trial in 2nd-line nonsquamous NSCLC, bavituximab+docetaxel was well-tolerated and demonstrated 60% improvement (11.7 vs 7.3mos.) in mOS (HR=.66; P=.11) compared to control. [2-19-16/Clin-Lung-Cancer-Jrnl: Ph2 Final Data, Dr. David Gerber etal http://tinyurl.com/z5a7fwu ]
METHODS:
597 patients with Stage IIIb/IV nonsquamous NSCLC that progressed on platinum-doublet chemotherapy were randomized 1:1 to receive up to 6 21-day cycles of docetaxel in combination with weekly 3mg/kg bavituximab (B+D) or placebo (D) until progression or toxicity. The primary endpoint was OS. Secondary endpoints included PFS, ORR, and safety.
RESULTS:
With 12mos. follow-up from the last patient randomized and ~85% of the targeted OS events reached, mOS was 10.5mos. (95% CI, 8.4-11.9) among 297 patients in B+D and 10.9mos. (95% CI, 9.2-12.1) among 300 patients in D (HR, 1.06; P=.533). PFS was 4.2mos. (95% CI, 3.9-4.6) in B+D and 4.1mos. (95% CI, 3.2-4.8) in D (HR, 1.02; P=.876). The ORR was 15% in B+D vs. 11% in D (odds ratio, 0.7; P=.15). The safety profile was similar between groups. Grade 3 or higher adverse events occurred in 68% of patients in B+D and 60% in D. In an exploratory analysis of OS for patients who received subsequent immune checkpoint inhibitors (ICI), the mOS was not reached (95% CI, 15.2-NA) in B+D (n=46) and 12.6mos. (95% CI, 10.4-17.8) in D (n=47) (HR=.46; P=.006).
CONCLUSIONS:
The combination of B+D was well-tolerated though no OS difference was observed compared to D alone in the ITT population of prev. treated nonsquamous NSCLC. An exploratory analysis of patients who received subsequent ICI found significantly longer OS in patients who received prior B+D than those who received D and support further clinical investigation of B+ICI in NSCLC.
= = = = = = = = = = = = = = = = =
Sunrise Biomarker studies - 4 announced thru ASCO'17, see http://tinyurl.com/ydhf6tfx
......#1 10-10-16/ESMO’16: B2GPI/200-240(30%pts) StatSig MOS 7.7=>13.2mos. http://tinyurl.com/hp73njt
......#2 12-7-16/WCLC’16(IASLC): “Complement & IL-10 Pathways: Pts Benefiting from Bavi+Doce” <=Presentation CANCELLED/”Anal.Not.Finished(IR)” http://tinyurl.com/z8cq8vx
......#3 4-3-17/AACR'17: "IFN-y Analysis In Blood & Tissue as a Potential Prognostic and/or Predictive Biomarker” See: http://tinyurl.com/ktzr782
......#4 6-3-17/ASCO'17: "Prelim. Correlative Analysis of PD-L1 Expression from the Sunrise Study” See ASCO'17: http://tinyurl.com/y93upatl

[biopharm]

Sunrise Biomarkers (#1/B2GPI #2/COMPL,IL10 #3/IFN-y #4/PD-L1)
...
...

Thanks for the compilation posts CJ and all Biomarkers were not made public, including CTCs etc etc and all Avid Bioservices CDMO shareholders should be questioning why Ampersand was the chosen one...

Why would Ampersand, that has a direct tie to other companies Biomarkers and blood tests / liquid biopsies etc etc would act so strangely to not seek patent infringements against others that USE PS Targeting data / research ...well, unless Ampersand had direct involvement with their partners ...or maybe is it part of some master plan we have not been told yet

Much more to surface ...as RareCyte showcases PS Targeting required liquid biopsies today
__________

Robert G. Shepler
Managing Director
Telegraph Hill Partners

Bob has been a corporate transactions specialist and investor since 1978, with a focus on strategic M&A transactions. Bob and Matt Mackowski partnered together in 1991 to form THP’s predecessor focused on investing in private healthcare companies. During his career, he has served on numerous company boards and completed over 200 M&A and financing transactions. Bob has represented THP on the boards of Kinetikos Medical (acquired by Integra), AcroMetrix (acquired by Life Technologies), Agena Bioscience, Akoya Biosciences, Aurora Discovery (acquired by NEXUS Biosystems), Applied Precision (acquired by GE), Dynex, LDR Spine (NASDAQ:LDRH), Estech (acquired by AtriCure), RareCyte, Sage Labs (acquired by Horizon Discovery) and Vidacare (acquired by Teleflex). He is currently an observer on the boards of Magstim and Precision NanoSystems. Prior to joining with Mr. Mackowski, Bob worked with Merrill Lynch & Co. as an officer in their San Francisco corporate finance office, where he managed financings and acquisitions for Fortune 500 and selected high growth companies. Bob received a BA from Duke University and an MBA from New York University.

Frank Witney, Ph.D.
Operating Partner
Ampersand

Frank, who joined Ampersand as an Operating Partner in 2016, serves as Chairman of Gyros Protein Technologies. Frank most recently served as CEO of Affymetrix, a leading provider of genomics and cell biology products that was sold in 2016 for $1.3 billion. Previously, Frank was CEO of Dionex, a leading provider of analytical instrumentation that was sold in 2011 for $2.1 billion. He also held senior executive positions at Perkin Elmer, Packard Bioscience and Bio-Rad Laboratories. Frank holds a Ph.D. in molecular and cellular biology from Indiana University.

http://rarecyte.com/board-of-directors/

_____________

Contributor Information
Daniel E Campton, Email: moc.etycerar@notpmacd.

Arturo B Ramirez, Email: moc.etycerar@zerimara.

Joshua J Nordberg, Email: moc.etycerar@grebdronj.

Nick Drovetto, Email: moc.etycerar@ottevordn.

Alisa C Clein, Email: ude.wu@nielca.

Paulina Varshavskaya, Email: moc.etycerar@ayaksvahsravp.

Barry H Friemel, Email: moc.etycerar@lemeirfb.

Steve Quarre, Email: moc.etycerar@errauqs.

Amy Breman, Email: ude.mcb@namerb.

Michael Dorschner, Email: ude.wu@dom.

Sibel Blau, Email: moc.nsm@ualblebis.

C Anthony Blau, Email: ude.wu@ualbt.

Daniel E Sabath, Email: ude.notgnihsaw.u@htabasd.

Jackie L Stilwell, Email: moc.etycerar@llewlitsj.

Eric P Kaldjian, Email: moc.etycerar@naijdlake.

Article information
BMC Cancer. 2015; 15: 360.
Published online 2015 May 6. doi: 10.1186/s12885-015-1383-x
PMCID: PMC4430903
PMID: 25944336
Daniel E Campton,#1 Arturo B Ramirez,#1 Joshua J Nordberg,1Nick Drovetto,1 Alisa C Clein,6 Paulina Varshavskaya,1 Barry H Friemel,1 Steve Quarre,1 Amy Breman,2 Michael Dorschner,3Sibel Blau,4 C Anthony Blau,5 Daniel E Sabath,6 Jackie L Stilwell,1 and Eric P Kaldjiancorresponding author1
1RareCyte, Inc, Seattle, WA USA
2Medical Genetics Laboratories, Baylor College of Medicine, Houston, USA
3Department of Pathology, University of Washington, Washington, USA
4Rainier Hematology-Oncology, Northwest Medical Specialties, Washington, USA
5Center for Cancer Innovation, University of Washington, Washington, USA
6Departments of Laboratory Medicine and Medicine, University of Washington, Washington, USA
Daniel E Campton, Email: moc.etycerar@notpmacd.
Contributor Information.
...
...
Received 2014 Oct 1; Accepted 2015 Apr 28.


High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining

Daniel E Campton, Arturo B Ramirez, [...], and Eric P Kaldjian

Additional article information

Abstract

Background

Circulating tumor cells (CTCs) are malignant cells that have migrated from solid cancers into the blood, where they are typically present in rare numbers. There is great interest in using CTCs to monitor response to therapies, to identify clinically actionable biomarkers, and to provide a non-invasive window on the molecular state of a tumor. Here we characterize the performance of the AccuCyte® – CyteFinder® system, a comprehensive, reproducible and highly sensitive platform for collecting, identifying and retrieving individual CTCs from microscopic slides for molecular analysis after automated immunofluorescence staining for epithelial markers.

Methods

All experiments employed a density-based cell separation apparatus (AccuCyte) to separate nucleated cells from the blood and transfer them to microscopic slides. After staining, the slides were imaged using a digital scanning microscope (CyteFinder). Precisely counted model CTCs (mCTCs) from four cancer cell lines were spiked into whole blood to determine recovery rates. Individual mCTCs were removed from slides using a single-cell retrieval device (CytePicker™) for whole genome amplification and subsequent analysis by PCR and Sanger sequencing, whole exome sequencing, or array-based comparative genomic hybridization. Clinical CTCs were evaluated in blood samples from patients with different cancers in comparison with the CellSearch® system.


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430903/

____________

Patents for Immune Design ( Merck involved in hostile takeover )

Vaccines for HSV-2
Patent number: 10391164
Abstract: Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural protein other than an envelope glycoprotein, e.g., a capsid or tegument protein. The vaccine is for use in either HSV-2 seropositive or seronegative subjects.
Type: Grant
Filed: December 14, 2016

Date of Patent: August 27, 2019

Assignee: IMMUNE DESIGN CORP.

Inventors:

Thomas W. Dubensky, Jr.,
Nancy A. Hosken,
Scott H. Robbins,
Margaret D. Moore

https://patents.justia.com/assignee/immune-design-corp

___________

Meet the RareCyte team at the Advances in CTCs

2-5 October 2019
Corfu, Greece

http://rarecyte.com/

___________

Management Team

Joe Victor
Chief Executive Officer

Joe Victor serves on the Board of Directors at Rarecyte and has been a Venture Partner with 5AM Ventures since 2016. Prior to his joining 5AM Ventures, Mr. Victor served as CEO of Startide Sciences, a 5AM Ventures portfolio company chartered to identify and develop innovative technologies in the Life Sciences research tools markets. Prior to Startide, Mr. Victor served as CEO of DVS Sciences (acquired by Fluidigm Inc.), and Applied Precision Inc (acquired by GE Healthcare). He currently serves as Executive Chairman on the boards of Biodesy and Purigen Biosystems as well as on the Boards of RareCyte, Precision Nanosystems, and Glencoe Software. Mr. Victor also serves as an advisory board member to the Harvard Program in Therapeutic Science and the UC Davis Ecosystem for Biophotonics Innovation. Mr. Victor has also held various executive management and technical positions in the high technology, aviation, and energy markets. Mr. Victor holds an MBA from UCLA and MS and BS degrees in engineering from the University of Washington.

Ron Seubert
Chief Technology Officer

Ron brings a wealth of corporate leadership and technical experience to RareCyte. Prior to founding RareCyte, he was a founder and CEO at Applied Precision, Inc. (API). API initially specialized in semi-conductors. The company eventually spun off this division and began creating innovative imaging solutions for life sciences. Ron was instrumental in launching the popular DeltaVision line of microscopes, including the DeltaVision Elite and DeltaVision OMX, one of the first super-resolution imaging systems on the market. The company was sold to GE Life Sciences in 2011. His professional experience spans decades and he holds several patents.

Eric Kaldjian MD
Chief Medical Officer

Eric earned his MD and trained in pathology at the University of Michigan. He was a research fellow at the National Cancer Institute and is certified by the American Board of Pathology. Before RareCyte he was the Medical Director of Companion Diagnostics at Ventana Medical Systems/Roche Tissue Diagnostics. Eric’s pharmaceutical experience has included discovery research, toxicology, and exploratory and late phase clinical development at Hoffmann-La Roche and Parke-Davis / Pfizer. He was a director of clinical genomics at Gene Logic and Chief Scientific Officer at Transgenomic. He has degree in chemistry from Harvard and studied music at Trinity College, Cambridge, England.

Tad George, Ph.D.
Senior VP, Bio R&D

Tad has over 15 years of startup experience dedicated to creating scientific markets for novel instrumentation platforms that span basic research, drug discovery and clinical applications. Prior to joining RareCyte, Tad has held similar positions at Biodesy, Inc. and DVS Sciences, and was Director of Biology at Amnis Corporation. Tad completed his B.A. in Biochemistry from the Univ. of Texas at Austin, Ph.D. in Immunology from UT Southwestern Medical Center at Dallas, and post-doctoral training at Immunex Corp. in Seattle.

Steve Reese
Senior VP, Engineering

Steve Reese comes to Rarecyte from his previous role as Principal Systems Engineer within the Genomics and Cellular Research division of GE Healthcare. He has been involved with guiding the development of more than 20 automated fluorescent imaging systems during his 28+ years with Applied Precision, GE Healthcare, and RareCyte. Steve’s forte is managing multi-discplined development teams from problem definition through invention, design, and product execution for sophisticated fluorescent imaging applied to blood and tissue based biological samples. Steve holds B.Eng in Electrical Engineering from Yale University where he was awarded the Becton Prize for Engineering.

Bryan Sullivan
Senior VP, Sales and Marketing

Bryan Sullivan is a Sales Executive with 33 years of experience in developing strategic business relationships, building and leading sales and marketing organizations most recently as a Global Business Director at GE Life Sciences. Prior to his time as Global Business Director, Bryan held various sales leadership roles at GE Life Sciences, Applied Precision, Siemens Medical and Baxter Healthcare. He earned his bachelor’s degree from Fordham University and his MBA from Pepperdine University.

Tony Dedeo
VP, Operations and Quality

Tony has over 18 years of experience within Operations and is responsible for Quality, Supply Chain, Materials, and Manufacturing at RareCyte. He brings a wealth of diverse experience from holding roles of increasing responsibility at Chrysler, Raytheon, Ingersoll Rand, and most recently Verathon Inc. where he led Operations for two FDA regulated manufacturing sites (US and Canada) producing Class I and Class II medical devices. He holds a B.S. degree in Mechanical Engineering from Purdue University and is a certified Lean and Six Sigma Expert.

Leighton Howells
VP, Business Development

Leighton has over 30 years of experience in developing, launching and commercializing new technology platforms for global markets. His technical and management career focused on the pioneer instrumentation and assays for High Throughput Screening, High Content Screening and highly multiplexed imaging to support pharmaceutical drug discover/development and diagnostics. With an extensive career at GE Healthcare in Life Sciences and Diagnostic business units, Leighton held leadership positions in R&D, Operations and Commercial organizations, additionally leading the acquisition and integration of several high-performance imaging companies. Most recently, Leighton was the Director of Operations, Pharma Services at NeoGenomics. Leighton holds a bachelor’s degree in biological sciences from the University of West England, Bristol.

A Dedicated Team with Depth and Experience in Life Science Leadership

Joe Victor
Chief Executive Officer
RareCyte, Inc

Joe Victor serves on the Board of Directors at Rarecyte and has been a Venture Partner with 5AM Ventures since 2016. Prior to his joining 5AM Ventures, Mr. Victor served as CEO of Startide Sciences, a 5AM Ventures portfolio company chartered to identify and develop innovative technologies in the Life Sciences research tools markets. Prior to Startide, Mr. Victor served as CEO of DVS Sciences (acquired by Fluidigm Inc.), and Applied Precision Inc (acquired by GE Healthcare). He currently serves as Executive Chairman on the boards of Biodesy and Purigen Biosystems as well as on the Boards of RareCyte, Precision Nanosystems, and Glencoe Software. Mr. Victor also serves as an advisory board member to the Harvard Program in Therapeutic Science and the UC Davis Ecosystem for Biophotonics Innovation. Mr. Victor has also held various executive management and technical positions in the high technology, aviation, and energy markets. Mr. Victor holds an MBA from UCLA and MS and BS degrees in engineering from the University of Washington.

Ron Seubert
Chief Technology Officer
RareCyte, Inc

Ron brings a wealth of corporate leadership and technical experience to RareCyte. Prior to founding RareCyte, he was a founder and CEO at Applied Precision, Inc. (API). API initially specialized in semi-conductors. The company eventually spun off this division and began creating innovative imaging solutions for life sciences. Ron was instrumental in launching the popular DeltaVision line of microscopes, including the DeltaVision Elite and DeltaVision OMX, one of the first super-resolution imaging systems on the market. The company was sold to GE Life Sciences in 2011. His professional experience spans decades and he holds several patents.

Robert G. Shepler
Managing Director
Telegraph Hill Partners

Bob has been a corporate transactions specialist and investor since 1978, with a focus on strategic M&A transactions. Bob and Matt Mackowski partnered together in 1991 to form THP’s predecessor focused on investing in private healthcare companies. During his career, he has served on numerous company boards and completed over 200 M&A and financing transactions. Bob has represented THP on the boards of Kinetikos Medical (acquired by Integra), AcroMetrix (acquired by Life Technologies), Agena Bioscience, Akoya Biosciences, Aurora Discovery (acquired by NEXUS Biosystems), Applied Precision (acquired by GE), Dynex, LDR Spine (NASDAQ:LDRH), Estech (acquired by AtriCure), RareCyte, Sage Labs (acquired by Horizon Discovery) and Vidacare (acquired by Teleflex). He is currently an observer on the boards of Magstim and Precision NanoSystems. Prior to joining with Mr. Mackowski, Bob worked with Merrill Lynch & Co. as an officer in their San Francisco corporate finance office, where he managed financings and acquisitions for Fortune 500 and selected high growth companies. Bob received a BA from Duke University and an MBA from New York University.

Frank Witney, Ph.D.
Operating Partner
Ampersand

Frank, who joined Ampersand as an Operating Partner in 2016, serves as Chairman of Gyros Protein Technologies. Frank most recently served as CEO of Affymetrix, a leading provider of genomics and cell biology products that was sold in 2016 for $1.3 billion. Previously, Frank was CEO of Dionex, a leading provider of analytical instrumentation that was sold in 2011 for $2.1 billion. He also held senior executive positions at Perkin Elmer, Packard Bioscience and Bio-Rad Laboratories. Frank holds a Ph.D. in molecular and cellular biology from Indiana University.

Brian Daniels, MD
Venture Partner
5AM Ventures

Brian Daniels, M.D. joined 5AM Ventures as a Venture Partner in 2014 and transitioned to Partner in 2018. Dr. Daniels previously spent over two decades in clinical drug development, including leading the Development and Medical Affairs at Bristol-Myers Squibb for the last ten years. He directed the development of numerous innovative medicines that have contributed to the improvement for patients across a range of serious diseases. These include: ORENCIA and NULOJIX in immunology/transplant, REYATAZ, DAKLINZA and BARACLUDE in virology, ONGLYZA, FARXIGA and MYALEPT in metabolics, ELIQUIS in CV and YERVOY, OPDIVO, SPRYCEL and IXEMPRA in oncology. Dr. Daniels is currently a Director at these 5AM companies: Spyryx Bioscience, Nohla Therapeutics, Rarecyte, and Ideaya Biosciences (independent). He leads the Clinical Advisory Board for Aprea Therapeutics and is the acting Chief Medical Officer for Expansion Therapeutics. He also served on the Scientific Advisory Board of Novira. Dr. Daniels received B.S. and M.S. degrees from MIT and his M.D. from Washington University in St. Louis. He trained in internal medicine at New York Hospital and Rheumatology/Immunology at UCSF. Dr. Daniels is based in the San Francisco, CA office.

_____


Ampersand has LOTS to lose and ties to Thermofisher and Merck now surfacing


Gyros Protein Technologies

Board of Directors

Frank Witney
Chairman

Frank Witney, Ph.D., served most recently as President, CEO of Affymetrix, Inc. until its acquisition by Thermo Fisher Scientific in March 2016. Prior to that role Frank served as President and CEO of Dionex Corporation from April 2009 to May 2011. Frank held the position of President and CEO of Panomics, Inc. from July 2002 to December 2008 leading to its acquisition by Affymetrix. Prior to that role, Frank had a variety of executive positions at Bio-Rad, Packard Bioscience and PerkinElmer. Frank received his Ph.D. in Molecular and Cellular Biology from Indiana University and did post-doctoral research at the NIH. Frank is a member of the Board of Directors of Cerus Corporation, Exagen Diagnostics, Inc., and Perkin Elmer.



David B. Patteson
Director

Operating Partner, Ampersand Capital Partners

David served as Executive Chairman of Protein Technologies, Inc. He concurrently serves as President and CEO of Advion, Inc. a life science instrument business sold to Bohui Innovation Technology in 2015. David also served as CEO of Advion BioSciences, a bioanalytical CRO business acquired by Quintiles Transnational in 2011, and CEO of Biotage, Inc. acquired by Pyrosequencing AB in 2003. David holds two separate B. S. degrees from The University of Richmond and Virginia Polytechnic Institute, and completed an International Management program through IMD in Lausanne, Switzerland.



Magnus Persson
Director

Magnus Persson, M.D. Ph.D., has 15 years of partner level experience in venture capital and has been a partner in two life sciences venture capital firms, one with its base in Sweden and with global reach and one in the Bay Area in California. Magnus has extensive experience in medicine, life sciences and biotech financing. He has led development teams of Phase II and III programs in the pharmaceutical industry. He has founded, and led private as well as public biotech and medtech companies as Chairman of the Board and Director in the Nordic Countries, Europe and USA. All in all, he has more than 90 Board years in the life science industry. Magnus has led audit and remuneration committees and several successful recruitment processes for senior management positions.



Hans Andreasson
Director

Investment Director, SLS Invest

Hans has 25 years of international experience in the life science industry. He has held various senior executive positions with Pharmacia, Pharmacia & Upjohn and Arthur D Little. He is a co-founder of the venture capital fund Innoventus which subsequently became part of SLS Invest. He is currently Vice Chairman of Oncolog Medical AB and a director of Action Pharma A/S, AdvanDx Inc, Medical Vision AB and Phasein AB. Hans holds an MSc in chemical engineering from Chalmers University of Technology and an MBA from INSEAD.



David J. Parker
Director

General Partner, Ampersand Capital Partners

Dave, who has more than 15 years of private equity experience, joined Ampersand in 1994. Dave’s board seats have included Bako, NOVEX, Signature Genomics and Roadrunner. Prior to joining Ampersand, Dave spent five years consulting at Bain and Mercer and four years in corporate lending at Bank of Boston. He holds a B.A. in Government and Economics from Dartmouth and an M.B.A. from Wharton.



Gerrit van den Dool
Director

Gerrit recently retired and before that served as Senior Vice President, Head of Research and Applied Solutions, Western Europe Commercial for the Life Science Business of Merck KGgA, Darmstadt. Prior to this Gerrit was Managing Director EMEA (Europe Middle East and Africa) at Sigma-Aldrich Corporation, the company he joined in 1999 and served in various sales and operational leadership roles, based in both the US and Europe. Prior to this he held a variety of positions at Amersham Pharmacia, Molecular Dynamics, Applied Biosystems and Spectra Physics. Gerrit holds an Engineering degree in Applied Physics.



Marina Pellon-Consunji
Director

Principal, Ampersand Capital Partners

Marina joined Ampersand in 2013. Prior to joining Ampersand, she was an Associate Director in Healthcare Investment Banking at UBS where she worked on a number of leveraged buyouts, mergers and acquisitions, and debt and equity financings for middle market healthcare companies. Prior to UBS, Marina worked at biochemistry laboratories at Harvard Medical School and Wellesley College. Marina holds a B.A. with Honors from Wellesley where she majored in Biological Chemistry and International Relations.

https://www.gyrosproteintechnologies.com/board-of-directors-gpt

[biopharm]

CJ, Biomarkers are the most important factor at this stage...as without Biomarkers based on PS Targeting...some can not gain fast ...very fast ..FDA approvals

I am only taking a small portion of a post that should be ready slowly...but all should see the Perkin Elmer ties ...actually 3 of them, well more if one includes Frank Witney now...our Ampersand Capital sidekick to Mark Bamforth and Patrick Walsh ...

Things will continue to become I increasingly, interesting around here ..

...
#4 6/3/17 ASCO’17 #11603 (Session: Tumor Biology)
“Preliminary Correlative Analysis of PD-L1 Expression from the Sunrise Study”
http://abstracts.asco.org/199/AbstView_199_190902.html
AUTHORS:
LEAD: Nikoletta Lea Kallinteris (PPHM)
Rachel E. Sanborn (Co-Dir., Thoracic Oncology Pgm, Robert W. Franz Cancer Res. Center, Earle A. Chiles Res. Inst., Providence CC, Portland; Honoraria=AstraZeneca; Consulting=Amgen/Ariad/DNA/PPHM/SeaGen; Funding=BMS/MedImmune/Merck)
Leora Horn (Oncologist/Vanderbilt-Ingram CC; Honoraria=Biodesix; Funding=AZN)
David E. Gerber (UTSW)
Ronald B. Natale (Med.Dir/Lung-Cancer-Pgm/Cedars-Sinai Medical Center; consult/funding=AstraZeneca)
Min Tang (PPHM)
Sean Downing (Scientist/Molecular Pathology, Foundation Medicine Inc., Cambridge MA) http://www.foundationmedicine.com ; disclosure=PerkinElmer)
Amanda Clement (Scientist/PerkinElmer; disclosure=Abbvie)
Tobias Guennel (Sen.Dir., Translational Informatics & Biometrics, Precision for Medicine, Frederick MD https://www.precisionmedicinegrp.com/pfm )
Joseph Shan (PPHM, VP/Clin+Reg)
SENIOR AUTHOR: Cliff Hoyt (Oncology Fellow/PerkinElmer)

I am sure some will figure it out sooner or later ....but I guess Ampersand can always just make a big splash announcement with Bio Rad ( has a subsidiary MorphoSys US ties to same MorphoSys that lost patent war to JnJ recently for MM ) and maybe Alice Schwartz ( Bio Rad Billionaire that buys Bavituximab ...hmmm) will put everyone in their place and she can just throw a twist into all this for all the greed that continues


_________

Frank Witney


July 22, 2016

Frank Witney BOD Perkin Elmer

http://ir.perkinelmer.com/news-releases/news-release-details/perkinelmer-elects-frank-witney-board-directors

_______________

Sept 6, 2016
Frank Witney Sep 5, 2016 details on deals and he knows the value of PS Targeting / diagnostics etc

https://cen.acs.org/articles/94/i35/CEN-Talks-Frank-Witney-executive.html

____________

Sept 19, 2016

Frank Witney into Ampersand Capital

http://ampersandcapital.com/wp-content/uploads/2016/09/Frank-Witney-Joins-Ampersand-as-Operating-Partner-9-19-16.pdf

____

Mr Bamforth, you can call Frank Witney now and maybe realize ...investigations are active and one whistleblower is not much to ask for when things are so obvious ...unless again, it was part of some plan... (though then we got John Stafford who just so happened to fell into this to allow things to happen ...kind of in a bind)

A "Rare Site" into how things go down does not happen very often...and so much more but Nantucket is a busy time of year at this time

_____

[Globewriter]

CJ, a material event for investigations ongoing with Gilead and David E Gerber and Joe Grogan as Avid Bioservices Mark Bamforth and Patrick Walsh remain silent

Gilead and a PS Targeting agent for Coronavirus and National Security Joe Grogan - Gilead ties is all the investigators require for now- that a message from bio and we will certainly hear how important PS Targeting is to the health of all as I only am relaying this info and PS Targeting was the target of all John Stafford initiatives that are being fully investigated by many more right now

Coronavirus uses flipped PS to enter ones cell and it will require a PS Targeting drug first

Joe Grogan
Assistant to The President
The White House The College of William and Mary - Marshall Wythe Law School
Washington D.C. Metro Area500+ connections

Experience
The White House
Assistant to the President, Director of the Domestic Policy Council
The White House
Feb 2019 – Present11 months
Office of Management and Budget
Associate Director, Health Programs
Office of Management and Budget
Mar 2017 – Feb 20192 years
Old Executive Office Building
Gilead Sciences
Government Affairs
Gilead Sciences
Nov 2011 – Mar 20175 years 5 months
Washington D.C. Metro Area
Head of Federal Affairs.
Head of Federal Affairs.
Amgen
Director, Global Regulatory Affairs and Safety
Amgen
Jun 2009 – Nov 20112 years 6 months
Washington D.C. Metro Area
Head of North American Regulatory Policy
Head of North American Regulatory Policy
The Marwood Group
Vice President
The Marwood Group
Aug 2008 – Jun 200911 months
Washington D.C. Metro Area
Advised investors on FDA regulatory risks of specific products and classes of products.
Advised investors on FDA regulatory risks of specific products and classes of products.
FDA
Senior Policy Advisor
FDA
Nov 2006 – Aug 20081 year 10 months
Washington D.C. Metro Area
Advised Commissioner of FDA on major regulatory, legislative and policy initiatives.
Advised Commissioner of FDA on major regulatory, legislative and policy initiatives.
Presidential Advisory Council on HIV and AIDS
Executive Director
Presidential Advisory Council on HIV and AIDS
May 2004 – Nov 20062 years 7 months
Washington D.C. Metro Area
Administration for Children and Families
Special Assistant
Administration for Children and Families
2001 – 20043 years